Review

International Journal of Obesity (2010) 34, 949–959; doi:10.1038/ijo.2009.286; published online 12 January 2010

Gluteofemoral body fat as a determinant of metabolic health

K N Manolopoulos1, F Karpe1,2 and K N Frayn1

  1. 1Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
  2. 2NIHR Oxford Biomedical Research Centre, ORH Trust, OCDEM, Churchill Hospital, Oxford, UK

Correspondence: Dr KN Manolopoulos, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK. E-mail: konstantinos.manolopoulos@ocdem.ox.ac.uk

Received 19 August 2009; Accepted 18 December 2009; Published online 12 January 2010.

Top

Abstract

Body fat distribution is an important metabolic and cardiovascular risk factor, because the proportion of abdominal to gluteofemoral body fat correlates with obesity-associated diseases and mortality. Here, we review the evidence and possible mechanisms that support a specific protective role of gluteofemoral body fat. Population studies show that an increased gluteofemoral fat mass is independently associated with a protective lipid and glucose profile, as well as a decrease in cardiovascular and metabolic risk. Studies of adipose tissue physiology in vitro and in vivo confirm distinct properties of the gluteofemoral fat depot with regards to lipolysis and fatty acid uptake: in day-to-day metabolism it appears to be more passive than the abdominal depot and it exerts its protective properties by long-term fatty acid storage. Further, a beneficial adipokine profile is associated with gluteofemoral fat. Leptin and adiponectin levels are positively associated with gluteofemoral fat while the level of inflammatory cytokines is negatively associated. Finally, loss of gluteofemoral fat, as observed in Cushing's syndrome and lipodystrophy is associated with an increased metabolic and cardiovascular risk. This underlines gluteofemoral fat's role as a determinant of health by the long-term entrapment of excess fatty acids, thus protecting from the adverse effects associated with ectopic fat deposition.

Keywords:

body fat distribution; gluteofemoral fat; adipose tissue metabolism; metabolic health; WHR

Top

Introduction

Obesity is defined as a body mass index (BMI) >30kgm–2 and an increased BMI has been associated with a high risk of cardiovascular disease and diabetes.1 It has long been known that body fat distribution is also an important risk factor: the proportion of abdominal to gluteofemoral body fat, as measured, for example, by the waist-to-hip ratio, correlates with obesity-associated diseases and mortality and is a stronger cardiovascular risk marker than BMI.2, 3, 4 Here, we review the evidence for gluteofemoral fat being protective and the possible mechanisms that may be involved.

Top

Body fat distribution and risk

Several population studies support the fact that obesity-associated health risks depend on the accumulation of abdominal fat. Abdominal obesity is associated with increased blood pressure and plasma triglyceride (TG) levels.2, 3 It is also an independent predictor for the development of type 2 diabetes.5

The adverse effect of abdominal obesity arises from the combination of subcutaneous adipose tissue dysfunction and the accumulation of visceral fat that becomes apparent when individuals with increased waist-to-hip ratio are studied with imaging techniques.6, 7, 8 The particular importance of visceral fat accumulation versus subcutaneous fat depot dysfunction has recently been challenged9, 10 as there is mounting evidence to support that visceral adipocytes are phenotypically different from subcutaneous adipocytes.11

Nevertheless, it is the protective role of lower body, that is, gluteofemoral fat that is striking. The protective properties of the lower-body fat depot have been confirmed in many studies conducted in subjects with a wide range of age, BMI and co-morbidities (Table 1). Gluteofemoral fat, as measured by thigh circumference, hip circumference or leg adipose tissue mass, is independently associated with lower total- and low-density lipoprotein-cholesterol, and total- and very-low-density lipoprotein–TG levels, and higher high-density lipoprotein-cholesterol levels.12, 13, 14, 15, 16, 17 Atherosclerotic protection is not only conveyed by an improved lipid profile, but also through direct effects on vascular health: increased gluteofemoral fat mass is associated with lower aortic calcification and arterial stiffness,18, 19, 20 as well as with a decreased progression of aortic calcification.21 Leg adipose tissue mass change after a 14-week intervention study with diet and exercise is inversely associated with diastolic blood pressure, low-density lipoprotein-cholesterol levels and the number of coronary heart disease-risk factors (that is, blood pressure, fasting plasma glucose levels and levels of individual lipid fractions).22 Further, lower-body fat is inversely associated with fasting insulin levels and insulin levels after an oral glucose load, and positively associated with insulin sensitivity.12, 17, 23, 24, 25 In healthy overweight and obese women, hip circumference and thigh adipose tissue mass are associated with a lower Hba1c and increased leptin levels.26


The protective effect of gluteofemoral fat has also been confirmed in large population studies. In the AusDiab study, a larger hip circumference was associated with a lower prevalence of undiagnosed diabetes mellitus and dyslipidaemia.27 The INTERHEART study, comprising 27000 participants, established an independent association between larger hip circumference and lower risk for myocardial infarction.4 In the prospective European Prospective Investigation into Cancer and Nutrition–Norfolk study, larger hip circumference was associated with a lower hazard ratio for coronary heart disease.28 Further, hip circumference was positively associated with plasma levels of ascorbic acid, an anti-oxidative factor thought to contribute to endothelial protection.29

Recent physiological and molecular studies elucidating the possible mechanisms that may contribute to the gluteofemoral depot's protective role will be the focus of this review. It has been suggested that subcutaneous adipose tissue acts as a buffer for the daily influx of dietary lipids, protecting other tissues from a lipid overflow with associated lipotoxicity.30 The protective properties of gluteofemoral fat could derive from a differential local handling of fatty acid uptake and release. Indeed, femoral fat accumulation that is typical of the female fat distribution pattern is associated with an elevated adipose tissue lipoprotein lipase activity.31, 32 Given the metabolic and cardiovascular protection that is conveyed by the gynoid fat distribution pattern, this supports the view of gluteofemoral fat being a protective ‘metabolic sink’.33

Another possibility is that there is differential secretion of adipose tissue-related proteins, that is, adipokines. As it will be discussed below, gluteofemoral adipose tissue could contribute to a protective adipokine profile by secreting more ‘beneficial’ adipokines and less pro-inflammatory molecules compared with abdominal fat.

Finally, conditions that result in the loss of gluteofemoral fat, as in chronic glucocorticoid excess in Cushing's syndrome (CS) or partial lipodystrophy, lead to metabolic abnormalities that underline the protective properties of this distinctive adipose tissue depot.

Top

Fatty acid storage and release

Adipose tissue metabolism is a complex and highly regulated process that depends on several factors.34 One of the main functions of subcutaneous adipose tissue is the short-term and long-term storage of energy as TG to re-supply the organism with energy in form of non-esterified fatty acids, released during periods of exercise, fasting or starvation. Important determinants of local adipose tissue fatty acid trafficking are the rate of lipolysis, the rate of TG storage, primarily taking place after meals, and the blood flow in the tissue beds.35 Variations in these factors may be responsible for the beneficial effects of gluteofemoral fat depots.

Insulin is a major suppressor of lipolysis in adipose tissue. Body fat distribution has an effect on the inhibition of lipolysis: isolated adipocytes from upper-body obese women respond less to insulin when compared with those of lower-body obese.36 Catecholamines increase lipolysis in isolated adipocytes. However, there are marked differences between depots with regards to this response. Abdominal adipocytes showed a four- to fivefold increase in lipolysis during noradrenaline stimulation when compared with gluteal adipocytes.37 This is mediated through a higher expression of beta-adrenoceptors in the abdominal depot.38

The uptake of meal fatty acids from TG-rich chylomicrons depends on the expression of lipoprotein lipase (LPL) by adipocytes. In isolated adipocytes and fat segments, LPL mRNA expression is higher in abdominal than in gluteal cells.39 However, the situation is probably more complex, not least because of the complex post-transcriptional regulation of LPL.40 This is observed when analyzing the sexual dimorphism of fat distribution: activity of LPL is higher in abdominal adipocytes from men and in gluteal adipocytes from women when compared with the other depot respectively.31, 39 In men, testosterone suppresses LPL activity in the thigh, thus contributing to abdominal fat accumulation.41 It is therefore likely that gender-specific fat depot formation is partly regulated by LPL.

As a result of the complexity of human adipose tissue metabolism, the study of fat depots in vivo is the only way that allows for the integration of factors not present in vitro. Upper-body fat is the major contributor of systemic non-esterified fatty acids, hence showing a higher lipolysis rate when compared with the lower-body fat depot.42, 43 The rate of action of the enzyme hormone-sensitive lipase, a key enzyme in lipolysis, is lower in the gluteal than the abdominal depot.44 Starvation for 72h results in increased lipolysis in the abdominal depot but not in gluteofemoral fat.45 During adrenaline stimulation, abdominal lipolysis appears to be higher than femoral lipolysis, when measured as glycerol release by microdialysis.46 Palmitate release, a direct marker of lipolysis, is lower in leg fat compared with the abdominal depot during systemic beta-adrenoceptor stimulation.47

Regional differences can also be found when studying fatty acid uptake in vivo. A consistent finding, much in line with lower lipolysis rates in gluteofemoral body fat, is that abdominal fat takes up meal-derived fatty acids more avidly than lower-body fat on a day-to-day short-term basis.48, 49 This supports the hypothesis of the subcutaneous fat being a metabolic ‘sink’, with the majority of daily fatty acid buffering being handled by abdominal fat. The exact fatty acid trafficking might, however, be more complex, given the presence of putative distinct very-low-density lipoprotein- and non-esterified fatty acid-turnover pathways, for instance. These, as well as the regulation of long-term fatty acid deposition in lower-body fat depots, are little understood and require further study.

Adipose tissue blood flow (ATBF) is an important determinant of fat metabolism that can only be studied in vivo. Variations in blood flow allow for the regulation of non-esterified fatty acid release into the systemic circulation and of substrate availability for LPL after a meal. Conversely, ATBF increases in periods of starvation and postprandially.50, 51 Interestingly, the postprandial rise in ATBF is not a direct insulin effect but is mainly mediated through catecholamines and nitric oxide.52, 53

ATBF changes of the abdominal fat depot have been well studied in different settings; however, little is known regarding ATBF regulation in the lower-body fat depot. Gluteal fat was shown to have lower basal ATBF,44 and in lean women, femoral ATBF showed an attenuated increase during systemic adrenaline stimulation compared with abdominal fat.46 Postprandially, ATBF increases in both the abdominal and femoral depots in women, but only in the abdominal depot in men.49 Further studies will be needed to elucidate the exact mechanisms behind differential ATBF regulation of the two depots.

In summary, upper- and lower-body fat show distinct properties with regards to lipolysis and fatty acid uptake. When looking at the short-term handling of fatty acids, the abdominal depot actively participates in daily fatty acid metabolism and seems to act as a buffer for the daily influx of dietary fatty acids.30 In contrast, the gluteofemoral depot appears to be more passive and exerts its protective properties in long-term fatty acid storage (Figure 1). This is evident in the accumulation of gluteofemoral fat associated with the typical female fat distribution.31 Female lower-body fat is only removed during periods of excessive energy demand, for example, lactation.54 In contrast, healthy women are more protected from cardiovascular events than men, until their body fat distribution changes with menopause (interestingly, toward the android distribution pattern).55, 56 Extrapolating this, gluteofemoral fat may protect our bodies, irrespective of gender, by trapping excess fatty acids and preventing chronic exposure to elevated lipid levels. The exact regulatory mechanisms of fatty acid release and storage and their effect on short- and long-term fatty acid metabolism remain to be analyzed.

Figure 1.
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Gluteofemoral adipose tissue function in daily metabolism (a); gluteofemoral tissue dysfunction and metabolic health (b). Abbreviations: FA, fatty acid(s); s.c., subcutaneous.

Full figure and legend (116K)

Top

Adipokine formation in regional adipose tissue

Adipose tissue is known to secrete several hormones termed adipokines. The term ‘adipokines’ accounts for the common source of these hormones57 but does not take into consideration that they are in fact secreted by different cell types within the tissue. Thus, while adipokines such as adiponectin and leptin are produced by adipocytes, interleukins are secreted mainly by resident macrophages. Wherever they come from, adipokines are part of a signalling cascade that is only partly understood, allowing for the communication between adipose tissue and other organs, primarily brain and liver. The existence of such a communication network is not surprising given the tissue's central role in fat storage and release and the need for coordination and control of appetite, hunger and satiety, which are subject to central regulation. The question that arises is whether the protective properties of lower-body fat are associated with a beneficial profile in its adipokine metabolism.

Differences in expression of adipokine genes and in secretion in vitro are well established when comparing subcutaneous and visceral fat.11, 58 However, little is known regarding differences between upper- and lower-body fat.

Leptin

One of the first adipokines discovered was leptin, a 16-kDa protein that is mainly secreted by adipocytes as a product of the LEP gene.59, 60 Leptin is thought to be pivotal in energy metabolism by regulating appetite and energy intake as a function of fat mass.61 Leptin levels are associated with the subcutaneous rather than the visceral fat depot and leptin mRNA is more abundant in subcutaneous adipocytes.6, 58, 62 Leptin secretion in vitro is higher in subcutaneous adipocytes compared with visceral adipocytes and this secretion rate correlates well with serum leptin levels.63 There are no studies that have compared regional leptin mRNA expression in subcutaneous adipose tissue; however, there are indirect suggestions that basal expression does not differ between abdominal and gluteofemoral fat.64, 65 Serum leptin increases in parallel with BMI and, interestingly, is higher in women.66, 67, 68, 69, 70 The sexual dimorphism in circulating leptin levels is apparent already in childhood71, 72 and has been attributed to differences in subcutaneous fat mass and adipocyte cell size.73, 74 But could gender differences in body fat distribution be indicative of a differential leptin production between depots? Leptin levels correlate with leg fat mass and hip circumference75, 76, 77 and, in obesity, are negatively correlated to waist-to-hip ratio.66, 78, 79 In men, interstitial leptin concentrations, as measured by microdialysis, are higher in subcutaneous femoral than abdominal fat.80 This is further supported by the finding that the leg is a net leptin producer, when measured directly.81 When comparing android to gynoid obesity, differences can be found in circadian serum leptin levels, with higher amplitude of secretion in lower-body obesity.82, 83 However, despite these associations a direct differential involvement of either depot remains to be proven. Given leptin's role as a feedback signal with regards to body fat mass and a modulator of metabolic processes,84 it remains speculative whether there is any special association with the lower-body fat depot. This is an area that needs further investigation.

Adiponectin

A beneficial association has also been shown for another adipokine—adiponectin. Adiponectin is exclusively secreted by adipocytes and is negatively correlated to body fat mass, that is, its serum levels are decreased in obesity.85, 86, 87 Interestingly, higher adiponectin levels are related to better glycaemic control and insulin sensitivity, a more favorable lipid profile and reduced inflammation in healthy individuals88, 89 and diabetic patients.90 Thus, it is believed that adiponectin provides a link between obesity and the development of insulin resistance and cardiovascular disease.91 Accordingly, regarding the influence of gluteofemoral body fat, adiponectin levels are positively associated with leg fat mass.92 Moreover, higher gluteofemoral fat mass results in higher adiponectin levels and increased insulin sensitivity.16, 93 There is a negative association between adiponectin and waist-to-hip ratio, central fat mass accumulation and visceral fat mass.6, 88, 94, 95, 96, 97 Further, in vitro studies have shown that adiponectin protein content and mRNA expression are lower in visceral adipocytes98 and that with increasing visceral fat mass adiponectin secretion from those cells is decreased, whereas secretion rates from subcutaneous adipocytes remain unaffected.99 There is also a differential expression pattern of adiponectin receptor 1 with high levels of expression in subcutaneous fat. Although there are no data regarding differences in adiponectin receptor expression levels between the upper- and lower-body fat depot, it is of interest that subcutaneous receptor expression is reduced in obesity and can be restored by weight loss.100 In summary, a favorable adiponectin profile could be facilitated by an increased lower-body fat depot.

Inflammatory cytokines

Alongside the ‘classic’ adipokines leptin and adiponectin, several so-called inflammatory cytokines have been identified to be secreted by adipose tissue. This is recognized as one of the links between obesity and the development of cardiovascular disease, insulin resistance and diabetes, because inflammatory processes are part of the pathophysiology of these diseases. The most widely analyzed cytokines are tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6).

TNF-α is secreted by many different cell types, including adipocytes, as a 17-kDa protein, which is derived by cleavage from an initially synthesized 26-kDa transmembrane monomeric protein.101, 102 Although adipocytes are capable of secreting TNF-α, it is now recognized that the main proportion of TNF-α secreted by adipose tissue originates from adipose tissue-resident macrophages and other cells of the stromavascular fraction.103 TNF-α is a strong inducer of lipolysis104 and data from rodents and humans support a role in the development of insulin resistance.105, 106, 107 The latter, however, has been challenged by others108 and although TNF-α levels are increased in obesity,109, 110 there is little direct release from abdominal subcutaneous adipose tissue in vivo.111 Interestingly, in a similar set of studies it was found that abdominal subcutaneous adipose tissue releases the soluble TNF receptor type 1 and that its levels correlate with BMI.112 Given that there is no association between body fat distribution and serum levels of TNF-α,113, 114 one could hypothesize that it is the secreted levels of soluble TNF receptor type 1, which determine the adverse properties of TNF-α in abdominal obesity.115 However, because there are no data regarding TNF-α secretion by lower-body fat depots, this remains to be further analyzed.

IL-6 is an inflammatory cytokine that, similarly to TNF-α, is secreted by a variety of cells and tissues,116 including adipose tissue. There, it is secreted both from adipocytes and stromavascular fraction cells and secretion levels correlate positively with obesity.117, 118 Systemic plasma levels of IL-6 correlate with visceral fat mass and there is a weak negative association with increasing thigh fat area.119 There are no studies comparing regional IL-6 production between upper- and lower-body fat, but direct regional in vivo measurement of IL-6 and IL-6 receptor concentrations showed abdominal tissue to release IL-6 but not its receptor.111, 112 Although insulin-resistance and cardiovascular disease are viewed as partly low-grade chronic inflammatory processes, the IL-6 role in the development of insulin-resistance remains controversial.120 There is a current lack of data on regional IL-6 release and this is an area of future research.

Other adipokines

Currently, there are several other adipokines known and some of them show interesting correlations between systemic levels and body fat distribution parameters. For instance, plasma levels of retinol-binding protein 4, a protein released from adipocytes and associated with insulin resistance,121 correlate with trunk fat mass.122, 123 Further, serum vaspin, an insulin-sensitizing adipokine, shows an interesting sexual dimorphism with levels higher in women.124 For these, and for other emerging adipokines, little is known regarding the specific role of regional adipose tissue in their production, secretion and function in human metabolism.

Top

Gluteofemoral fat loss and disease

So far, the beneficial properties of the gluteofemoral fat depot have been highlighted. A further perspective underlining its protective features is to elucidate what happens when substantial amounts of gluteofemoral fat mass are lost. Indeed, lower-body fat loss is associated with metabolic abnormalities.

Glucocorticoid excess

Cortisol, the main glucocorticoid in humans, which is secreted by the adrenal cortex, exerts important catabolic functions in fuel metabolism. The effect of cortisol on body fat and metabolic health is observed in states of glucocorticoid excess such as Cushing's syndrome, in which a marked fat re-distribution is pathognomonic. Fat redistribution in CS is a complex area, as glucocorticoid excess not only reduces the gluteofemoral fat depot, but also changes adipocyte function in the abdominal depot (reviewed in125). Glucocorticoid excess in CS patients results in an increase of total fat mass, mostly confined to the abdominal fat depot.126 This abdominal fat accumulation might be due to an increase in abdominal LPL activity and a decreased lipolytic capacity of the enlarged abdominal adipocytes.127 Furthermore, corticosteroid exposure results in a decrease of abdominal adipose tissue lipolysis in vivo.128 Abdominal fat accumulation in CS has been attributed to the redistribution of peripheral fat to the visceral fat depot.129, 130 However, it is interesting to note that visceral fat accumulation in CS does not correlate with lipid and glucose profiles.131 It is well established that glucocorticoid excess, as observed in CS, is associated with an adverse glucose and lipid profile that increases metabolic and cardiovascular risk.132, 133 So far, the direct association of gluteofemoral fat loss and metabolic health in CS has not been studied. However, the relative mass loss because of fat redistribution provides a plausible mechanism for the adverse effect of glucocorticoid excess on metabolic and cardiovascular risk.

Lipodystrophy

The deleterious effect of gluteofemoral fat loss becomes most evident in lipodystrophic syndromes. Lipodystrophy is characterized by partial or total absence of adipose tissue and can be either inherited or acquired.134 The loss of adipose tissue leads to ectopic fat accumulation, in line with the view of subcutaneous fat being a ‘metabolic sink’ for excess energy.33, 135 Ectopic fat accumulation occurs in the liver, pancreas and muscle. Further, depending on the type of lipodystrophy, there is fat accumulation in specific non-atrophic fat depots, for instance the neck.

Patients suffering from autosomal dominant familial partial lipodystrophy Dunnigan-type lose primarily the subcutaneous adipose tissue of their arms and legs.135 These patients show severe insulin resistance, lipid profile abnormalities, hypertension and develop diabetes.136, 137, 138 Several mutations in the LMNA gene as well as in the PPARG gene were identified as the molecular mechanism responsible for the development of familial partial lipodystrophy.134 The PPARG-mutations provide a possible link between adipose tissue dysfunction and the metabolic profile associated with this type of lipodystrophy, given that adipose tissue appears to be unresponsive to physiological regulatory mechanisms in these patients.138

In contrast, patients with acquired partial lipodystrophy (Barraquer–Simons’ syndrome), who progressively lose their adipose tissue from the face and upper body but deposit large amounts of fat in the gluteofemoral region, show mild insulin resistance and have a lower prevalence of diabetes compared with other lipodystrophic syndromes.134, 139

Top

Conclusion

Body fat distribution is a major determinant of metabolic health and gluteofemoral adipose tissue exerts specific functional properties that are associated with an improved metabolic and cardiovascular risk profile. The protective properties of gluteofemoral fat have been confirmed in large population studies. Evidence arising from in vitro and in vivo studies suggests that this is due to a differential regulation of lower-body fatty acid release and uptake at the level of the adipocyte that results in the long-term entrapment of fatty acids in this depot and protection from ectopic fat accumulation. This becomes even more evident in states of gluteofemoral fat loss as in glucocorticoid excess and lipodystrophic syndromes that are associated with increased metabolic and cardiovascular risk. In addition, gluteofemoral adipose tissue could convey protection through a beneficial adipokine profile. This is suggested by the favorable association of leptin and adiponectin levels with gluteofemoral fat mass, while it remains to be proven for other emerging adipokines. The recent discovery of novel gene loci involved in the regulation of body fat distribution, beyond the male–female dichotomy, provides an appealing area for further investigation.140 Future research will also show if the protective properties of gluteofemoral body fat can be used to attenuate metabolic and cardiovascular risk, as already observed in the redistribution of body fat associated with the clinical use of thiazolidinediones.141, 142

Top

Conflict of interest

The authors declare no conflict of interest.

Top

References

  1. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341: 427–434. | Article | PubMed | ISI | ChemPort |
  2. Canoy D, Luben R, Welch A, Bingham S, Wareham N, Day N et al. Fat distribution, body mass index and blood pressure in 22090 men and women in the Norfolk cohort of the European prospective investigation into cancer and nutrition (EPIC-Norfolk) study. J Hypertens 2004; 22: 2067–2074. | Article | PubMed | ISI | ChemPort |
  3. Grundy SM, Adams-Huet B, Vega GL. Variable contributions of fat content and distribution to metabolic syndrome risk factors. Metab Syndr Relat Disord 2008; 6: 281–288. | Article | PubMed | ChemPort |
  4. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640–1649. | Article | PubMed | ISI
  5. Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The monica/kora augsburg cohort study. Am J Clin Nutr 2006; 84: 483–489. | PubMed | ChemPort |
  6. Taksali SE, Caprio S, Dziura J, Dufour S, Cali AM, Goodman TR et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes 2008; 57: 367–371. | Article | PubMed | ChemPort |
  7. Hayashi T, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in japanese americans. Diabetes 2008; 57: 1269–1275. | Article | PubMed | ChemPort |
  8. Sam S, Haffner S, Davidson MH, D’Agostino Sr RB, Feinstein S, Kondos G et al. Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes 2008; 57: 2022–2027. | Article | PubMed | ChemPort |
  9. Frayn KN. Visceral fat and insulin resistance--causative or correlative? Br J Nutr 2000; 83(Suppl 1): S71–S77. | Article | PubMed | ISI | ChemPort |
  10. Miles JM, Jensen MD. Counterpoint: visceral adiposity is not causally related to insulin resistance. Diabetes Care 2005; 28: 2326–2328. | Article | PubMed
  11. Perrini S, Laviola L, Cignarelli A, Melchiorre M, De Stefano F, Caccioppoli C et al. Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia 2008; 51: 155–164. | Article | PubMed | ChemPort |
  12. Seidell JC, Perusse L, Despres JP, Bouchard C. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec family study. Am J Clin Nutr 2001; 74: 315–321. | PubMed | ISI | ChemPort |
  13. Terry RB, Stefanick ML, Haskell WL, Wood PD. Contributions of regional adipose tissue depots to plasma lipoprotein concentrations in overweight men and women: possible protective effects of thigh fat. Metabolism 1991; 40: 733–740. | Article | PubMed | ChemPort |
  14. Williams MJ, Hunter GR, Kekes-Szabo T, Snyder S, Treuth MS. Regional fat distribution in women and risk of cardiovascular disease. Am J Clin Nutr 1997; 65: 855–860. | PubMed | ISI | ChemPort |
  15. Snijder MB, Visser M, Dekker JM, Goodpaster BH, Harris TB, Kritchevsky SB et al. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The health ABC study. Diabetologia 2005; 48: 301–308. | Article | PubMed | ISI | ChemPort |
  16. Buemann B, Astrup A, Pedersen O, Black E, Holst C, Toubro S et al. Possible role of adiponectin and insulin sensitivity in mediating the favorable effects of lower-body fat mass on blood lipids. J Clin Endocrinol Metab 2006; 91: 1698–1704. | Article | PubMed | ChemPort |
  17. Yim JE, Heshka S, Albu JB, Heymsfield S, Gallagher D. Femoral-gluteal subcutaneous and intermuscular adipose tissues have independent and opposing relationships with CVD risk. J Appl Physiol 2008; 104: 700–707. | Article | PubMed
  18. Ferreira I, Snijder MB, Twisk JW, van Mechelen W, Kemper HC, Seidell JC et al. Central fat mass versus peripheral fat and lean mass: opposite (adverse versus favorable) associations with arterial stiffness? The amsterdam growth and health longitudinal study. J Clin Endocrinol Metab 2004; 89: 2632–2639. | Article | PubMed | ISI | ChemPort |
  19. Snijder MB, Henry RM, Visser M, Dekker JM, Seidell JC, Ferreira I et al. Regional body composition as a determinant of arterial stiffness in the elderly: the Hoorn Study. J Hypertens 2004; 22: 2339–2347. | Article | PubMed | ChemPort |
  20. Tanko LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 2003; 107: 1626–1631. | Article | PubMed
  21. Tanko LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Central and peripheral fat mass have contrasting effect on the progression of aortic calcification in postmenopausal women. Eur Heart J 2003; 24: 1531–1537. | Article | PubMed
  22. Okura T, Nakata Y, Yamabuki K, Tanaka K. Regional body composition changes exhibit opposing effects on coronary heart disease risk factors. Arterioscler Thromb Vasc Biol 2004; 24: 923–929. | Article | PubMed | ISI | ChemPort |
  23. Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM. Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am J Physiol Endocrinol Metab 2002; 282: E1023–E1028. | PubMed | ChemPort |
  24. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Yudkin JS et al. Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn Study. Diabetes Care 2004; 27: 372–377. | Article | PubMed
  25. Snijder MB, Dekker JM, Visser M, Yudkin JS, Stehouwer CD, Bouter LM et al. Larger thigh and hip circumferences are associated with better glucose tolerance: the Hoorn Study. Obes Res 2003; 11: 104–111. | Article | PubMed | ISI
  26. Rocha PM, Barata JT, Teixeira PJ, Ross R, Sardinha LB. Independent and opposite associations of hip and waist circumference with metabolic syndrome components and with inflammatory and atherothrombotic risk factors in overweight and obese women. Metabolism 2008; 57: 1315–1322. | Article | PubMed | ChemPort |
  27. Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE. Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the Ausdiab Study. Int J Obes Relat Metab Disord 2004; 28: 402–409. | Article | PubMed | ChemPort |
  28. Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A, Bingham S et al. Body fat distribution and risk of coronary heart disease in men and women in the european prospective investigation into cancer and nutrition in norfolk cohort: a population-based prospective study. Circulation 2007; 116: 2933–2943. | Article | PubMed
  29. Canoy D, Wareham N, Welch A, Bingham S, Luben R, Day N et al. Plasma ascorbic acid concentrations and fat distribution in 19068 British men and women in the European prospective investigation into cancer and nutrition Norfolk cohort study. Am J Clin Nutr 2005; 82: 1203–1209. | PubMed | ChemPort |
  30. Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologia 2002; 45: 1201–1210. | Article | PubMed | ISI | ChemPort |
  31. Pouliot MC, Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A et al. Regional variation in adipose tissue lipoprotein lipase activity: association with plasma high density lipoprotein levels. Eur J Clin Invest 1991; 21: 398–405. | Article | PubMed | ChemPort |
  32. Bos G, Snijder MB, Nijpels G, Dekker JM, Stehouwer CD, Bouter LM et al. Opposite contributions of trunk and leg fat mass with plasma lipase activities: the Hoorn Study. Obes Res 2005; 13: 1817–1823. | Article | PubMed | ISI | ChemPort |
  33. Lemieux I. Energy partitioning in gluteal-femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk? Arterioscler Thromb Vasc Biol 2004; 24: 795–797. | Article | PubMed | ChemPort |
  34. Frayn KN, Arner P, Yki-Jarvinen H. Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays Biochem 2006; 42: 89–103. | Article | PubMed | ChemPort |
  35. Ruge T, Hodson L, Cheeseman J, Dennis AL, Fielding BA, Humphreys SM et al. Fasted to fed trafficking of fatty acids in human adipose tissue reveals a novel regulatory step for enhanced fat storage. J Clin Endocrinol Metab 2009; 94: 1781–1788. | Article | PubMed | ChemPort |
  36. Dowling HJ, Fried SK, Pi-Sunyer FX. Insulin resistance in adipocytes of obese women: effects of body fat distribution and race. Metabolism 1995; 44: 987–995. | Article | PubMed | ChemPort |
  37. Wahrenberg H, Lonnqvist F, Arner P. Mechanisms underlying regional differences in lipolysis in human adipose tissue. J Clin Invest 1989; 84: 458–467. | Article | PubMed | ChemPort |
  38. Arner P, Hellstrom L, Wahrenberg H, Bronnegard M. Beta-adrenoceptor expression in human fat cells from different regions. J Clin Invest 1990; 86: 1595–1600. | Article | PubMed | ChemPort |
  39. Arner P, Lithell H, Wahrenberg H, Bronnegard M. Expression of lipoprotein lipase in different human subcutaneous adipose tissue regions. J Lipid Res 1991; 32: 423–429. | PubMed | ChemPort |
  40. Doolittle MH, Ben-Zeev O, Elovson J, Martin D, Kirchgessner TG. The response of lipoprotein lipase to feeding and fasting. Evidence for posttranslational regulation. J Biol Chem 1990; 265: 4570–4577. | PubMed | ChemPort |
  41. Ramirez ME, McMurry MP, Wiebke GA, Felten KJ, Ren K, Meikle AW et al. Evidence for sex steroid inhibition of lipoprotein lipase in men: comparison of abdominal and femoral adipose tissue. Metabolism 1997; 46: 179–185. | Article | PubMed | ChemPort |
  42. Martin ML, Jensen MD. Effects of body fat distribution on regional lipolysis in obesity. J Clin Invest 1991; 88: 609–613. | Article | PubMed | ChemPort |
  43. Guo Z, Hensrud DD, Johnson CM, Jensen MD. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 1999; 48: 1586–1592. | Article | PubMed | ChemPort |
  44. Tan GD, Goossens GH, Humphreys SM, Vidal H, Karpe F. Upper and lower-body adipose tissue function: a direct comparison of fat mobilization in humans. Obes Res 2004; 12: 114–118. | Article | PubMed
  45. Gjedsted J, Gormsen LC, Nielsen S, Schmitz O, Djurhuus CB, Keiding S et al. Effects of a 3-day fast on regional lipid and glucose metabolism in human skeletal muscle and adipose tissue. Acta Physiol (Oxf) 2007; 191: 205–216. | Article | PubMed | ChemPort |
  46. Horowitz JF, Klein S. Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper-body obese women. Am J Physiol Endocrinol Metab 2000; 278: E1144–E1152. | PubMed | ChemPort |
  47. Guo Z, Johnson CM, Jensen MD. Regional lipolytic responses to isoproterenol in women. Am J Physiol 1997; 273 (1 Part 1): E108–E112. | PubMed | ChemPort |
  48. Koutsari C, Snozek CL, Jensen MD. Plasma nefa storage in adipose tissue in the postprandial state: sex-related and regional differences. Diabetologia 2008; 51: 2041–2048. | Article | PubMed | ChemPort |
  49. Romanski SA, Nelson RM, Jensen MD. Meal fatty acid uptake in adipose tissue: gender effects in nonobese humans. Am J Physiol Endocrinol Metab 2000; 279: E455–E462. | PubMed | ChemPort |
  50. Patel JN, Coppack SW, Goldstein DS, Miles JM, Eisenhofer G. Norepinephrine spillover from human adipose tissue before and after a 72-hour fast. J Clin Endocrinol Metab 2002; 87: 3373–3377. | Article | PubMed | ChemPort |
  51. Summers LK, Samra JS, Humphreys SM, Morris RJ, Frayn KN. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 1996; 91: 679–683. | PubMed | ChemPort |
  52. Ardilouze JL, Fielding BA, Currie JM, Frayn KN, Karpe F. Nitric oxide and beta-adrenergic stimulation are major regulators of preprandial and postprandial subcutaneous adipose tissue blood flow in humans. Circulation 2004; 109: 47–52. | Article | PubMed | ChemPort |
  53. Karpe F, Fielding BA, Ardilouze JL, Ilic V, Macdonald IA, Frayn KN. Effects of insulin on adipose tissue blood flow in man. J Physiol 2002; 540 (Part 3): 1087–1093. | Article | PubMed | ChemPort |
  54. Kramer FM, Stunkard AJ, Marshall KA, McKinney S, Liebschutz J. Breast-feeding reduces maternal lower-body fat. J Am Diet Assoc 1993; 93: 429–433. | Article | PubMed | ChemPort |
  55. Piche ME, Lapointe A, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J et al. Regional body fat distribution and metabolic profile in postmenopausal women. Metabolism 2008; 57: 1101–1107. | Article | PubMed | ChemPort |
  56. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr 1992; 55: 950–954. | PubMed | ISI | ChemPort |
  57. Trayhurn P, Rayner DV. Hormones and the ob gene product (leptin) in the control of energy balance. Biochem Soc Trans 1996; 24: 565–570. | PubMed | ChemPort |
  58. Montague CT, Prins JB, Sanders L, Digby JE, O′Rahilly S. Depot- and sex-specific differences in human leptin mrna expression: implications for the control of regional fat distribution. Diabetes 1997; 46: 342–347. | Article | PubMed | ISI | ChemPort |
  59. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–432. | Article | PubMed | ISI | ChemPort |
  60. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543–546. | Article | PubMed | ISI | ChemPort |
  61. Bluher S, Mantzoros CS. Leptin in humans: lessons from translational research. Am J Clin Nutr 2009; 89: 991S–997S. | Article | PubMed | ChemPort |
  62. Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 2002; 51: 1005–1015. | Article | PubMed | ISI | ChemPort |
  63. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998; 47: 913–917. | Article | PubMed | ISI | ChemPort |
  64. Chaparro J, Reeds DN, Wen W, Xueping E, Klein S, Semenkovich CF et al. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism 2005; 54: 561–567. | Article | PubMed | ChemPort |
  65. Papaspyrou-Rao S, Schneider SH, Petersen RN, Fried SK. Dexamethasone increases leptin expression in humans in vivo. J Clin Endocrinol Metab 1997; 82: 1635–1637. | Article | PubMed | ChemPort |
  66. Liuzzi A, Savia G, Tagliaferri M, Lucantoni R, Berselli ME, Petroni ML et al. Serum leptin concentration in moderate and severe obesity: relationship with clinical, anthropometric and metabolic factors. Int J Obes Relat Metab Disord 1999; 23: 1066–1073. | Article | PubMed | ChemPort |
  67. Ho SC, Tai ES, Eng PH, Ramli A, Tan CE, Fok AC. A study in the relationships between leptin, insulin, and body fat in asian subjects. Int J Obes Relat Metab Disord 1999; 23: 246–252. | Article | PubMed | ChemPort |
  68. Vettor R, De Pergola G, Pagano C, Englaro P, Laudadio E, Giorgino F et al. Gender differences in serum leptin in obese people: relationships with testosterone, body fat distribution and insulin sensitivity. Eur J Clin Invest 1997; 27: 1016–1024. | Article | PubMed | ChemPort |
  69. Shimizu H, Shimomura Y, Hayashi R, Ohtani K, Sato N, Futawatari T et al. Serum leptin concentration is associated with total body fat mass, but not abdominal fat distribution. Int J Obes Relat Metab Disord 1997; 21: 536–541. | Article | PubMed | ChemPort |
  70. Saad MF, Damani S, Gingerich RL, Riad-Gabriel MG, Khan A, Boyadjian R et al. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 1997; 82: 579–584. | Article | PubMed | ISI | ChemPort |
  71. Caprio S, Tamborlane WV, Silver D, Robinson C, Leibel R, McCarthy S et al. Hyperleptinemia: an early sign of juvenile obesity. Relations to body fat depots and insulin concentrations. Am J Physiol 1996; 271 (3 Part 1): E626–E630. | PubMed | ChemPort |
  72. Garnett SP, Hogler W, Blades B, Baur LA, Peat J, Lee J et al. Relation between hormones and body composition, including bone, in prepubertal children. Am J Clin Nutr 2004; 80: 966–972. | PubMed | ISI | ChemPort |
  73. Couillard C, Mauriege P, Imbeault P, Prud’homme D, Nadeau A, Tremblay A et al. Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. Int J Obes Relat Metab Disord 2000; 24: 782–788. | Article | PubMed | ChemPort |
  74. Baumgartner RN, Ross RR, Waters DL, Brooks WM, Morley JE, Montoya GD et al. Serum leptin in elderly people: associations with sex hormones, insulin, and adipose tissue volumes. Obes Res 1999; 7: 141–149. | PubMed | ChemPort |
  75. Staiger H, Tschritter O, Machann J, Thamer C, Fritsche A, Maerker E et al. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 2003; 11: 368–372. | Article | PubMed | ChemPort |
  76. Rissanen P, Makimattila S, Vehmas T, Taavitsainen M, Rissanen A. Effect of weight loss and regional fat distribution on plasma leptin concentration in obese women. Int J Obes Relat Metab Disord 1999; 23: 645–649. | Article | PubMed | ChemPort |
  77. Bennett FI, McFarlane-Anderson N, Wilks R, Luke A, Cooper RS, Forrester TE. Leptin concentration in women is influenced by regional distribution of adipose tissue. Am J Clin Nutr 1997; 66: 1340–1344. | PubMed | ChemPort |
  78. Lonnqvist F, Wennlund A, Arner P. Relationship between circulating leptin and peripheral fat distribution in obese subjects. Int J Obes Relat Metab Disord 1997; 21: 255–260. | Article | PubMed | ChemPort |
  79. Minocci A, Savia G, Lucantoni R, Berselli ME, Tagliaferri M, Calo G et al. Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obes Relat Metab Disord 2000; 24: 1139–1144. | Article | PubMed | ChemPort |
  80. Nielsen NB, Hojbjerre L, Sonne MP, Alibegovic AC, Vaag A, Dela F et al. Interstitial concentrations of adipokines in subcutaneous abdominal and femoral adipose tissue. Regul Pept 2009; 155: 39–45. | Article | PubMed | ChemPort |
  81. Jensen MD, Moller N, Nair KS, Eisenberg P, Landt M, Klein S. Regional leptin kinetics in humans. Am J Clin Nutr 1999; 69: 18–21. | PubMed | ChemPort |
  82. Perfetto F, Tarquini R, Cornelissen G, Mello G, Tempestini A, Gaudiano P et al. Circadian phase difference of leptin in android versus gynoid obesity. Peptides 2004; 25: 1297–1306. | Article | PubMed | ChemPort |
  83. Langendonk JG, Pijl H, Toornvliet AC, Burggraaf J, Frolich M, Schoemaker RC et al. Circadian rhythm of plasma leptin levels in upper and lower-body obese women: influence of body fat distribution and weight loss. J Clin Endocrinol Metab 1998; 83: 1706–1712. | Article | PubMed | ISI | ChemPort |
  84. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006; 393 (Part 1): 7–20. | Article | PubMed | ChemPort |
  85. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to c1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746–26749. | Article | PubMed | ISI | ChemPort |
  86. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83. | Article | PubMed | ISI | ChemPort |
  87. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. Cdna cloning and expression of a novel adipose specific collagen-like factor, apm1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286–289. | Article | PubMed | ISI | ChemPort |
  88. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459–469. | PubMed | ISI | ChemPort |
  89. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52: 1779–1785. | Article | PubMed | ISI | ChemPort |
  90. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4542–4548. | Article | PubMed | ISI | ChemPort |
  91. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007; 18: 263–270. | Article | PubMed | ChemPort |
  92. Snijder MB, Flyvbjerg A, Stehouwer CD, Frystyk J, Henry RM, Seidell JC et al. Relationship of adiposity with arterial stiffness as mediated by adiponectin in older men and women: the Hoorn Study. Eur J Endocrinol 2009; 160: 387–395. | Article | PubMed | ChemPort |
  93. Buemann B, Sorensen TI, Pedersen O, Black E, Holst C, Toubro S et al. Lower-body fat mass as an independent marker of insulin sensitivity--the role of adiponectin. Int J Obes (Lond) 2005; 29: 624–631. | Article | PubMed | ChemPort |
  94. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003; 88: 4823–4831. | Article | PubMed | ISI | ChemPort |
  95. Hanley AJ, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfeld C, Saad MF et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab 2007; 92: 2665–2671. | Article | PubMed | ChemPort |
  96. Vilarrasa N, Vendrell J, Maravall J, Broch M, Estepa A, Megia A et al. Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population. Clin Endocrinol (Oxf) 2005; 63: 329–335. | Article | PubMed | ChemPort |
  97. Park KG, Park KS, Kim MJ, Kim HS, Suh YS, Ahn JD et al. Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract 2004; 63: 135–142. | Article | PubMed | ChemPort |
  98. Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ et al. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res 2002; 34: 650–654. | Article | PubMed | ISI | ChemPort |
  99. Drolet R, Belanger C, Fortier M, Huot C, Mailloux J, Legare D et al. Fat depot-specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity (Silver Spring) 2009; 17: 424–430. | Article | PubMed | ChemPort |
  100. Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity (Silver Spring) 2006; 14: 28–35. | Article | PubMed | ChemPort |
  101. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45–53. | Article | PubMed | ISI | ChemPort |
  102. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729–733. | Article | PubMed | ISI | ChemPort |
  103. Fain JN, Bahouth SW, Madan AK. Tnfalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 2004; 28: 616–622. | Article | PubMed | ChemPort |
  104. Langin D, Arner P. Importance of TNFalpha and neutral lipases in human adipose tissue lipolysis. Trends Endocrinol Metab 2006; 17: 314–320. | Article | PubMed | ISI | ChemPort |
  105. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87–91. | Article | PubMed | ISI | ChemPort |
  106. Plomgaard P, Nielsen AR, Fischer CP, Mortensen OH, Broholm C, Penkowa M et al. Associations between insulin resistance and TNF-αalpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia 2007; 50: 2562–2571. | Article | PubMed | ChemPort |
  107. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-αlpha function. Nature 1997; 389: 610–614. | Article | PubMed | ISI | ChemPort |
  108. Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B et al. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 2004; 47: 1029–1037. | PubMed | ChemPort |
  109. Zahorska-Markiewicz B, Janowska J, Olszanecka-Glinianowicz M, Zurakowski A. Serum concentrations of TNF-αalpha and soluble TNF-αalpha receptors in obesity. Int J Obes Relat Metab Disord 2000; 24: 1392–1395. | Article | PubMed | ChemPort |
  110. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K et al. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 859–862. | Article | PubMed | ISI | ChemPort |
  111. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196–4200. | Article | PubMed | ISI | ChemPort |
  112. Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 1999; 277 (6 Part 1): E971–E975. | PubMed | ChemPort |
  113. Perry CD, Alekel DL, Ritland LM, Bhupathiraju SN, Stewart JW, Hanson LN et al. Centrally located body fat is related to inflammatory markers in healthy postmenopausal women. Menopause 2008; 15 (4 Part 1): 619–627. | Article | PubMed
  114. Good M, Newell FM, Haupt LM, Whitehead JP, Hutley LJ, Prins JB. TNF and TNF receptor expression and insulin sensitivity in human omental and subcutaneous adipose tissue--influence of BMI and adipose distribution. Diab Vasc Dis Res 2006; 3: 26–33. | Article | PubMed
  115. Hauner H, Bender M, Haastert B, Hube F. Plasma concentrations of soluble TNF-αalpha receptors in obese subjects. Int J Obes Relat Metab Disord 1998; 22: 1239–1243. | Article | PubMed | ChemPort |
  116. Kamimura D, Ishihara K, Hirano T. Il-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003; 149: 1–38. | PubMed | ChemPort |
  117. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273–2282. | Article | PubMed | ISI | ChemPort |
  118. Kern PA, Ranganathan S, Li CL, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol-Endocrinol Metab 2001; 280: E745–E751. | PubMed | ChemPort |
  119. Beasley LE, Koster A, Newman AB, Javaid MK, Ferrucci L, Kritchevsky SB et al. Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity (Silver Spring) 2009; 17: 1062–1069. | Article | PubMed
  120. Hoene M, Weigert C. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev 2008; 9: 20–29. | PubMed | ChemPort |
  121. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356–362. | Article | PubMed | ISI | ChemPort |
  122. Gavi S, Stuart LM, Kelly P, Melendez MM, Mynarcik DC, Gelato MC et al. Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. J Clin Endocrinol Metab 2007; 92: 1886–1890. | Article | PubMed | ChemPort |
  123. Gavi S, Qurashi S, Stuart LM, Lau R, Melendez MM, Mynarcik DC et al. Influence of age on the association of retinol-binding protein 4 with metabolic syndrome. Obesity (Silver Spring) 2008; 16: 893–895. | Article | PubMed | ChemPort |
  124. Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372–377. | Article | PubMed | ChemPort |
  125. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 2008; 197: 189–204. | Article | PubMed | ChemPort |
  126. Burt MG, Gibney J, Ho KK. Characterization of the metabolic phenotypes of Cushing's syndrome and growth hormone deficiency: a study of body composition and energy metabolism. Clin Endocrinol (Oxf) 2006; 64: 436–443. | Article | PubMed
  127. Rebuffe-Scrive M, Krotkiewski M, Elfverson J, Bjorntorp P. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. J Clin Endocrinol Metab 1988; 67: 1122–1128. | Article | PubMed | ChemPort |
  128. Samra JS, Clark ML, Humphreys SM, MacDonald IA, Bannister PA, Frayn KN. Effects of physiological hypercortisolemia on the regulation of lipolysis in subcutaneous adipose tissue. J Clin Endocrinol Metab 1998; 83: 626–631. | Article | PubMed | ChemPort |
  129. Mayo-Smith W, Hayes CW, Biller BM, Klibanski A, Rosenthal H, Rosenthal DI. Body fat distribution measured with ct: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology 1989; 170: 515–518. | PubMed | ChemPort |
  130. Wajchenberg BL, Bosco A, Marone MM, Levin S, Rocha M, Lerario AC et al. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in cushing′s disease. J Clin Endocrinol Metab 1995; 80: 2791–2794. | Article | PubMed | ChemPort |
  131. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP et al. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol 2003; 149: 561–567. | Article | PubMed | ChemPort |
  132. Friedman TC, Mastorakos G, Newman TD, Mullen NM, Horton EG, Costello R et al. Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome x and niddm. Endocr J 1996; 43: 645–655. | Article | PubMed | ChemPort |
  133. Walker BR. Cortisol--cause and cure for metabolic syndrome? Diabet Med 2006; 23: 1281–1288. | Article | PubMed | ChemPort |
  134. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350: 1220–1234. | Article | PubMed | ISI | ChemPort |
  135. Garg A, Peshock RM, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 1999; 84: 170–174. | Article | PubMed | ISI | ChemPort |
  136. Schmidt HH, Genschel J, Baier P, Schmidt M, Ockenga J, Tietge UJ et al. Dyslipemia in familial partial lipodystrophy caused by an r482w mutation in the lmna gene. J Clin Endocrinol Metab 2001; 86: 2289–2295. | Article | PubMed | ChemPort |
  137. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA et al. Dominant negative mutations in human ppargamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880–883. | Article | PubMed | ISI | ChemPort |
  138. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003; 52: 910–917. | Article | PubMed | ISI | ChemPort |
  139. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 2004; 83: 18–34. | Article | PubMed | ChemPort |
  140. Lindgren CM, Heid IM, Randall JC, Lamina C, Steinthorsdottir V, Qi L et al. Genome-wide association scan meta-analysis identifies three loci influencing adiposity and fat distribution. PLoS Genet 2009; 5: e1000508. | Article | PubMed | ChemPort |
  141. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784–2791. | Article | PubMed | ChemPort |
  142. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23: 1067–1071. | Article | PubMed | ChemPort |
  143. Albu JB, Kenya S, He Q, Wainwright M, Berk ES, Heshka S et al. Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese hiv-infected women. Am J Clin Nutr 2007; 86: 100–106. | PubMed | ChemPort |
Top

Acknowledgements

We thank the Wellcome Trust for support of our work.

Top

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated

NEWS AND VIEWS

Impact of Abdominal Adiposity on Cardiovascular Disease Predictors: What Is the Missing Link?

American Journal of Hypertension News and Views

You are what you secrete

Nature Medicine News and Views (01 Aug 2001)

Extra navigation

.

naturejobs

natureevents

ADVERTISEMENT